Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently in phase II clinical trials for thymic carcinoma in patients previously treated with chemotherapy. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. Tiziana Life Sciences’ research team has discovered that Bcl-3 has a prominent role in the metastasis of mammary cancers, and has elucidated the mechanism of Bcl-3 action to be a regulator of cancer cell motility. Tiziana has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in aggressive breast cancers, but across the clinical spectrum of breast disease. The Company anticipates that Bcl-3 will progress to clinical trials in 2016.
Show more
Type
Public
HQ
London, GB
Founded
2013
Size (employees)
6 (est)+20%
Tiziana Life Sciences was founded in 2013 and is headquartered in London, GB
Report incorrect company information

Tiziana Life Sciences Office Locations

Tiziana Life Sciences has an office in London
London, GB (HQ)
18 South St
Show all (1)
Report incorrect company information

Tiziana Life Sciences Financials and Metrics

Tiziana Life Sciences Financials

Tiziana Life Sciences's revenue was reported to be (£6.29 m) in FY, 2015 which is a 691.8% increase from the previous period.
GBP

Net income (FY, 2016)

(7.2 m)

EBITDA (FY, 2016)

(7.3 m)

EBIT (FY, 2016)

(7.3 m)

Market capitalization (31-Oct-2017)

142.4 m

Closing share price (31-Oct-2017)

1.5

Cash (31-Dec-2016)

4.7 m
Tiziana Life Sciences's current market capitalization is £142.4 m.
GBPFY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2014FY, 2015FY, 2016

Revenue

99 k116 k405 k311 k91.7 k56.1 k187.7 k(82 k)(195 k)(794 k)(6.3 m)

Revenue growth, %

692%

Cost of goods sold

45 k40 k209 k108 k20.4 k11 k69.9 k

Gross profit

54 k76 k196 k203 k71.3 k45 k117.9 k
GBPFY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

157.5 k2.2 m1.1 m6.6 k996 k771 k942 k508 k588 k25.2 k30.4 k69.4 k33 k4 k2.3 m8.9 m4.7 m

Accounts Receivable

54 k35 k60 k56 k16 k23.8 k38.4 k

Inventories

1 k4 k20 k7 k28.6 k38.2 k10.5 k

Current Assets

236.4 k2.6 m1.4 m677.4 k1.5 m1.9 m1.3 m873 k954 k221.4 k165.2 k182.7 k462 k27 k2.5 m9.3 m5 m
GBPFY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2014FY, 2015FY, 2016

Net Income

(553.9 k)(987.3 k)(2.3 m)(2.3 m)(2 m)(1.4 m)(2.1 m)(2.3 m)(2.4 m)(1.4 m)(729.9 k)(1.1 m)(778 k)(653 k)(3.3 m)(8.6 m)(7.2 m)

Cash From Operating Activities

534.7 k1.1 m2.5 m1.8 m1.6 m1.8 m1.3 m2.2 m2.2 m(914.4 k)(547.6 k)(403.8 k)(853 k)(210 k)(2.2 m)(5.5 m)(5.1 m)

Cash From Financing Activities

392.7 k4.7 m1.3 m488.5 k2 m1.7 m1.4 m1.7 m2.3 m451.2 k598.7 k554.7 k1.5 m67 k4.4 m12.1 m1.2 m

Net Change in Cash

405.3 k170.1 k178.8 k211.3 k117 k120 k18 k8 k102 k(563.9 k)8.3 k48.6 k33 k(29 k)2.3 m6.6 m(4.2 m)
GBPY, 2016

Financial Leverage

1.5 x
Show all financial metrics
Report incorrect company information

Tiziana Life Sciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Tiziana Life Sciences News and Updates

Report incorrect company information